Testosterone and prostate safety

Prostate Cancer: Principles and Practice

Volumn , Issue , 2005, Pages 213-221

  Morales, Alvaro ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33749264005     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (55)

1. Werner AA. The male climacteric: Report of two hundred and seventy three cases JAMA 1946;132:188-175.
2. Orrego JJ, Dimaraki E, Symons K, Barkan AL. Physiological testosterone replenishment in healthy elderly men does not normalize pituitary growth hormone output: Evidence against the connection between senile hypogonadism and somatopause. J Clin Endocrinol Metab 2004;87:3255-3260.
3. Hak AE, Witteman JCM, deJong FH, et al. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: The Rotterdam Study. J Clin Endocrinol Metab 2002,87:3632-3639.
4. Malkin CJ, Pugh PJ, Jones RD, et al. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in men. J Clin Endocrinol Metab 2004;89:3313-3318.
5. Liva SM, Voskhul RR. Testosterone acts directly on CD4+ lymphocytes to increase IL-10 production. J Immunol 2001;167:2060-2067.
6. Liverman CT, Blazer DG (eds). Institute of Medicine Report:Testosterone and Aging. Committee on Assessing the Need for Clinical Trials of Testosterone Replacement Therapy. National Academies Press, 2004.
7. Goderie-Plomp HM, van der Klift M, de Ronde W, et al. Endogenous sex hormones, sex hormone-binding globulin and the risk of incident vertebral fractures in elderly men and women: The Rotterdam Study. J Clin Endocrinol Metab 2004;89:3261-3269.
8. Bhasin S, Sing AB, Mac P, et al. Managing risk of prostate disease during testosterone replacement therapy of older men: Recommendations for a standard monitoring plan. J Androl 2003;24:299-306.
9. Zittzman M, Depenbusch M, Gromoll J, Nieschlag E. Prostate volume and growth in testosterone-substituted hypogonadal men are dependent on the CAG repeat polymorphism of the androgen receptor gene: a longitudinal pharmacogenetic study. J Clin Endocrinol Metab 2003;88:2049-2054.
10. Isaacs JT. Testosterone and the prostate. In Nieschlag E, Behre HM (eds): Testosterone, action deficiency, substitution, 3rd ed. Cambridge, UK: Cambridge University Press, 2004, pp 347-374.
11. Litvinov IV, De Marzo AM, Isaacs JT. Is the Achilles’ heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab 2003,88:2972-2982.
12. Bonkhoff H, Stein U, Aumüller, Remberger K. Differential expression of 5-alpha reductase isoenzyme in the human prostate and prostatic carcinoma. Prostate 1996;29:261-267.
13. Bayne CW, Ross M, Miller WR, Habib F. A new role for 5α-reductase type 1 in prostate growth and disease. Elect J Oncol 2002;152-57.
14. Nelson WG, De Marzo AM, Isaacs JT. Mechanisms of disease: Prostate cancer. N Engl J Med 2003;349:366-361.
15. Morales A. Androgen replacement therapy and prostate safety. Eur Urol 2002;41:113-120.
16. Marcelli M, Cunningham GR. Hormonal signaling in prostatic hyperplasia and neoplasia. J Clin Endocrinol Metab 1999;84:3463-3468.
17. Gann PH, Hennekens CH, Longcope C, et al. A prospective study of hormone plasma levels, non-hormonal factors and development of benign prostatic hyperplasia. Prostate 1995;26:40-49.
18. Kunelius P, Lukkarinen O, Anukksela ML, et al. The effect of transdermal dehydrotestosterone in the aging male: a prospective, randomized, double blind study. J Clin Endocrinol Metab 2002;87:1467-1472.
19. Wang C, Swerdloff RS. Editorial: Should the non-aromatizable androgen dehydrotestosterone be considered as an alternative to testosterone in the treatment of the andropause? J Clin Endocrinol Metab 2002;87:1462-1466.
20. Carson C III, Rittmaster R. The role of dehydrotestosterone in benign prostatic hyperplasia. Urology 2003;61:2-7.
21. Behre HM. Prostate volume in treated and untreated hypogonadal men in comparison to age-matched controls. Clin Endocrinol (Oxf) 1994;40:341-349.
22. Meikle AW, Arver S, Dobbs AS, et al. Prostate size in hypogonadal men treated with a nonscrotal permeation enhanced testosterone transdermal system. Urology 1997;49:191-196.
23. Tenover JL. Androgen deficiency in aging men. Aging Male 1998; (Suppl. 1):16-21.
24. Wright EJ, Fang J, Metter EJ, et al. Prostate specific antigen predicts the long-term risk of prostate enlargement: Results of the Baltimore Longitudinal Study of Aging. J Urol 2002;167:2484-2488.
25. Wang C, Swerdloff RS, Iranmanesh A, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 2000;85:2839-2853.
26. Swerdloff RS, Wang C. Three year follow-up of androgen treatment in hypogonadal men: preliminary report with testosterone gel. Aging Male 2003;6:207-211.
27. Wang C, Cunningham G, Dobbs A, et al. Long-term testosterone gel (Androgel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004;89:2085-2098.
28. McNicholas TA, Dean JD, Mulder H, et al. A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function. BJUI 2003;91:69-74.
29. AUA Practice Guidelines Committee. AUA Guideline on Management of Benign Prostatic Hyperplasia (2003). Chapter 1. Diagnosis and Treatment Recommendations. J Urol 2003;170:530-547.
30. Eaton NE, Reeves GK, Appleby PB, et al Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies. Br J Cancer 1990;80:930-934.
31. Shaneyfelt T, Husein R, Bubley G, et al. Hormonal predictors of prostate cancer: a meta-analysis. J Clin Oncol 2000;18:847-853.
32. Slater S, Oliver RTD. Testosterone: its role in the development of prostate cancer and potential risks for use as hormone replacement therapy. Drugs Aging 2000;17:431-439.
33. Mohr BA, Feldman HA, Kalih LA, et al. Are serum hormones associated with the risk of prostate cancer? Prospective results from the Massachusetts Male Aging Study. Urology 2001;57:930-935.
34. Parsons JK, Carter HB, Landis P, et al. High serum free testosterone is associated with an increased risk of prostate cancer: Results from the Baltimore Longitudinal Study on Aging. J Urol 2004;171:116[Abstract 439].
35. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride in the development of prostate cancer. N Engl J Med 2003;349:215-224.
36. Morgentaler A, Bruning CO III, DeWolff WC. Occult prostate cancer in men with low serum testosterone levels. JAMA 1996; 276:1904-1906
37. Knudsen KE, Arden KC, Cavanee WK. Multiple G1 regulatory elements control the androgen dependent proliferation of prostate carcinoma cells. J Biol Chem 1998;273:2013-2022.
38. Morales A, Connolly J, Burr R, Bruce AW. The use of radioactive phosphorus to treat bone pain in metastatica carcinoma of the prostate. Can Med Ass J 1970;103:372-375.
39. Prehn RT. On the prevention and therapy of prostate cancer by androgen administration. Cancer Res 1999;59:4161-4164.
40. Alagartè-Génin M, Cussenot O, Costa P. Prevention of prostate cancer by androgens: experimental paradox or clinical reality. Eur Urol 2004;46:285-295.
41. McKeehan WL, Adams PS, Rosser MP. Direct mitogenic effects of insulin, epidermal growth factor, glucocorticoid, cholera toxin, unknown pituitary factors and possibly prolactin, but not androgen on normal rat prostate epithelial cells in serum-free primary cell culture. Cancer Res 1984;44:1998-2010.
42. Stattin P, Soderberg S, Halmans G, et al. Leptin is associated with increased prostate cancer risk: A nested case-referent study. J Clin Endocrinol Metab 2001;86:1341-1345.
43. Plackson LA, Penson DF, Vaughn TL, et al. Cigarette smoking and risk of prostate cancer in middle age men. Cancer Epidemiol Biomarkers Prevention 2003;12:604-609.
44. Colao A, Vitale G, Di Sarno A, et al. Prolactin and prostate hypertrophy: A pilot observational, prospective, case control study in men with prolactinoma. J Clin Endocrinol Metab 2004;89:2770-2775.
45. Figueroa JA, De Raad S, Tadlock L, Speights VO, et al. Differential expression of insulin-like growth factor binding proteins in low versus high Gleason score prostate cancer. J Urol 1998;159:1379-1383.
46. Cohen P, Peehl DM, Graves HC, Rosenfeld RG. Biologic effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J Endocrinol 1994;142:407-415.
47. Harman SM, Metter EJ, Blackman MR, et al. Serum levels of insulinlike growth factor I (IGF-I), IGF-binding protein-3, and prostate specific antigen as predictors of clinical prostate cancer. J Clin Endocrinol Metab 2000;85:4258-4265.
48. Le Roux CW, Jenkins PJ, Chew SL, et al. Growth hormone replacement does not increase serum prostate-specific antigen in hypopituitary men over 50 years. Eur J Endocrinol 2002;147:59-63.
49. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-35.
50. Curran MJ, Bihrle W III. Dramatic rise in PSA after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate. Urology 1999;53:423-424.
51. Rhoden EL, Morgentaler A. Testosterone replacement therapy in hypogonadal men at risk for prostate cancer: Results of 1 year of treatment in men with prostatic intraepithelial neoplasia. J Urol 2003;170:2348-2351.
52. Nieschlag E, Behre HM (eds). Testosterone: Action- Deficiency-Substitution. Cambridge, UK: Cambridge University Press, 2004.
53. Zhang PL, Rosen S, Veeramachaneni R, et al. Association between prostate cancer and serum testosterone levels. Prostate 2002;53:179-182.
54. Fang J, Metter EJ, Landis P, et al. PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml. Urology 2002;59:889-893.
55. Morales A, Buvat J, Gooren LJ, et al. Endocrine aspects of sexual dysfunction in men. J Sexual Med 2004;1:69-75.